| Old Articles: <Older 46921-46930 Newer> |
|---|
 |
The Motley Fool
February 3, 2011
Thomas Lee |
Boston Scientific Wants to Be a Rock Star. But First, It Needs Some Stars Boston Scientific has been talking the talk of late. But its walk the past few years can be best described as a limp.   |
The Motley Fool
February 3, 2011
Sean Williams |
At This Rate, This Company May Go Bankrupt Within 5 Years A cash-rich balance sheet may not save this company from bankruptcy. |
The Motley Fool
February 3, 2011
Anders Bylund |
Stock Misses Earnings; Solar Industry Rallies If MEMC's assumptions are correct, solar stocks could have a banner year in 2011. |
The Motley Fool
February 3, 2011
Christopher Barker |
Silver Silver Everywhere Silver Miners to benefit from further cross-listings on U.S. exchanges. |
The Motley Fool
February 2, 2011
Rick Aristotle Munarriz |
More Lovin' for Sirius XM Morgan Stanley warms up to satellite radio. |
The Motley Fool
February 2, 2011
Rich Smith |
United Technologies Loves to Fly On Wednesday, UTC announced that it's taking a minority interest (no word on exactly how minor) in Eclipse Aerospace, maker of the Eclipse 500 "very light" business jet. |
The Motley Fool
February 2, 2011
Bryan Hinmon |
Are Home Health Stocks Too Cheap? Home health agency stocks are cheap -- is now a time to buy? |
The Motley Fool
February 2, 2011
Brian Stoffel |
What's It Going to Take to Move Activision Blizzard? Let's dissect four theories as to why the company's stock isn't moving. |
The Motley Fool
February 2, 2011
Brian Orelli |
Pfizer's Newest Acquisition Target The pharma giant decided to cut potential acquisitions from its revenue guidance and instead spend the money on share buybacks. |
The Motley Fool
February 2, 2011
Brian Orelli |
A Deeper Dive Into Biogen's Revenue Growth On the surface, it looks like Biogen Idec is handling the entrance of Novartis' new oral multiple sclerosis drug, Gilenya, quite well. The real picture is a little bleaker. |
| <Older 46921-46930 Newer> Return to current articles. |
